<DOC>
	<DOC>NCT00169702</DOC>
	<brief_summary>The study is a prospective, randomized, open-label study.</brief_summary>
	<brief_title>The Effect of a Weight Management Program During Treatment With Olanzapine</brief_title>
	<detailed_description>The principal objective of this trial is to investigate the effect of a comprehensive behavioural treatment program on weight gain in schizophrenic patients under olanzapine treatment, and on subjective well-being.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSMIV) criteria for schizophrenia Ages between 18 and 65 Informed consent Weight gain of at least 1.5 kg in the first 4 weeks A sufficient understanding to participate adequately in the weight management program Patients must agree to cooperate with all tests and examinations required by the protocol. Each patient must understand the nature of the study and must sign an informed consent document. Serious, unstable somatic illnesses Illnesses associated with weight gain including renal and endocrine diseases Weight change greater than 3 kg in the preceding three months Weight gain less than 1.5 kg in the first 4 weeks</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>Schizophrenia, weight management programme</keyword>
</DOC>